Today we will run through one way of estimating the intrinsic value of Vor Biopharma Inc. (NASDAQ:VOR) by taking the expected future cash flows and discounting them to today's value. One way to ...

Thousands of workers — many of them immigrants — who help keep the city’s airports running are now entitled to paid time off and health care benefits, under an expanded state labor law ...

Vor Bio is licensing global rights to a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last ...

CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has ...

Less than two months after Vor Bio telegraphed a strategic review, the former cell therapy biotech has made a surprise comeback with a potential $4 billion deal licensing a China-made autoimmune ...

Shares of Vor Bio are up 120% in pre-market trade on Thursday. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do ...

Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.

Discover the $8 billion plan to transform LaGuardia Airport, exploring its historical context and the details behind its expansion efforts. The video covers an overview of LaGuardia prior to ...

CAMBRIDGE, Mass. - Vor Bio, Inc. (NASDAQ:VOR), a clinical-stage biotech company currently trading at $0.54 per share, has secured exclusive rights to develop and commercialize telitacicept outside ...

PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset & $175M Private Placement ...

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, ...